Showing results (1701-1710 of 1,814) with videos related to
Sort By:
Pageof 182
American Journal of Respiratory and Critical Care Medicine|March 13, 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Courtney Crim, Gerard J Criner, et al.Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2019
A Multidisciplinary Toxicity Team for Cancer Immunotherapy-Related Adverse EventsJarushka Naidoo, Jiajia Zhang, Evan J Lipson, et al.Nature Communications|January 22, 2014
Kinase fusions are frequent in Spitz tumours and spitzoid melanomasThomas Wiesner, Jie He, Roman Yelensky, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 24, 2016
Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic AlterationsKai Wang, Jeffery S Russell, Jessica D McDermott, et al.Nature Communications|July 18, 2020
Femtosecond exciton dynamics in WSe2 optical waveguidesAaron J Sternbach, Simone Latini, Sanghoon Chae, et al.Journal for Immunotherapy of Cancer|July 28, 2022
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancerAnn W Silk, Christopher A Barker, Shailender Bhatia, et al.Oncology|May 22, 2016
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid CarcinomaAndreas M Heilmann, Vivek Subbiah, Kai Wang, et al.Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stabilityYujie Zhao, Jarushka Naidoo, Michael Conroy, et al.The New England Journal of Medicine|January 5, 2022
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced MelanomaHussein A Tawbi, Dirk Schadendorf, Evan J Lipson, et al.Pageof 182